• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Waters and Genovis Enter Biopharmaceutical Partnership

    Frontage Acquires Ocean Ridge Biosciences

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lessons Learned: Choosing and Managing a CDMO

    Waters and Genovis Enter Biopharmaceutical Partnership

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Syngene

    PCI Pharma Services

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Syngene

    Almac Group

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: Joanne Anderson

    Scottish CMO Sets Up Shop in U.S.

    Newsmakers: Joanne Anderson
    Related CONTENT
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    • Metrics Names Stephanie Emory Associate Director of Pharma Development
    • BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    • Vetter Development Service
    06.06.17
    Sterile manufacturing specialist Symbiosis Pharmaceutical Services is a contract manufacturing organization (CMO) that specializes in the cGMP manufacture and sterile fill/finish of vials for clinical trials and commercial supply. Back in 2015, the UK-based company made the decision to strategically focus on the North American market after identifying a surge in funding for early stage biotechs. Earlier this year, Symbiosis opened a new commercial site in Cambridge, MA, to support its East and West Coast clients with its vial-filling services including liquid and lyophilized formulations in injectable dosage forms. Joanne Anderson, business development director at Symbiosis, talked with Contract Pharma about the company’s recent expansion as well as biologics fill/finish trends in today’s market. —TW


    Contract Pharma: How would you describe the current biologics fill/finish market?
    Joanne Anderson:
    The market will always be subject to change, but we believe there is significant market demand for aseptic manufacturing capabilities for biologics. This has been boosted by a positive investment climate in the biotech space, particularly in the U.S., which in turn is facilitating the development of new biological drugs, increasing the depth of an industry-wide drug pipeline and fueling demand for outsourced manufacturing services to bring products to the clinical trial stage.

    Within the fill/finish market customers need to choose whether to work with a big one-stop-shop service provider or smaller, more specialist and flexible partners. Specifically, it comes down to what will get the client to clinical trials in the safest and quickest route they possibly can.

    CP: What are the main trends in the biologics fill/finish market today?
    JA:
    Fill/finish is historically one of the most outsourced activities due to the high cost of equipment, quality infrastructure and facility requirements. Many contract manufacturing organizations (CMOs) have experienced a surge in the market due to several factors, including the decrease in the amount of high-quality CMO capacity available for aseptic fill/finish.

    There are specialist CMOs such as Symbiosis whose focus is on fill finish and we have built an operational flexibility to move our clients through the clinical development stages quicker than our larger, less nimble competitors. In contrast, several of the larger CMOs are looking to extend their service offering to align with the one-stop-shop service provider model.

    The industry is also seeing lots of consolidation, with many mergers and acquisitions taking place to allow CMOs to expand their service offerings and reach new geographies. This is leading to a revival of the ‘one-stop-shop’ model that big pharma was made up of years ago.

    We believe that there is a need for specialist CMOs to deliver the agile and responsive service that is required in today’s complex and fast-paced drug development landscape.

    There is a positive investor climate in the market, which means that drug developers are under increasing pressure to demonstrate the success of their promising molecules at an early stage. Experience has taught us that there is a real market demand for rapid access to manufacturing slots. This can help to make up for lost time in the earlier project stages.

    This is particularly true in the area of biologics where complex and novel drugs require specialist expertise and a flexible and cost effective process. Therefore, opportunities to speed up time to clinical trials and minimize losses during drug product manufacture are demanded, and our ability to meet these needs is a major contributing factor to our growth and success.

    We also find that small and mid-sized drug developers value cultural fit and true partnerships when selecting a CMO for their projects. Often this requires a smaller, nimble CMO that can deliver a personalized service. 

    CP: What do you believe are the key factors to success in the biologics fill/finish market?
    JA:
    Success in fill/finish outsourcing is underpinned by technical capabilities and effective communication on both sides of the supply contract. The relationship between the client and service provider is fundamental.

    As a result, we are seeing more and more clients moving away from tactical outsourcing initiatives in favor of a relationship-oriented strategic partnership with CMO partners across a collaborative supply chain.

    Due to the nature and complexity of sterile fill/finish, most drug developers need a long-term vendor that will invest time, energy and resource into achieving a productive outcome.

    The long-term benefit for a CMO like Symbiosis is we grow and scale-up as clients’ products move through phases. It also gives us a strong understanding of each client’s product and process, which we may have developed, adding huge value when it comes to increased batch outputs and meeting clinical deadlines. 

    We also increasingly see that new drugs are being developed for very specialized disease states and unmet needs. This results in much smaller patient populations and hence smaller batch sizes, which has a significant impact on operations and the technologies that are the best fit for the application.

    We have focused on flexible equipment and single-use disposable technologies at Symbiosis to enable fast product release, the flexibility to produce small sterile batches for trials and eliminate potential for cross-contamination.

    Having specific experience in handling biologic drug substances is a significant advantage for a specialist CMO like us as it reduces the potential for process loss and risks when handling some very high value materials.

    CP: And what are the main barriers/issues in the market?
    JA:
    Fill/finish is often characterized as the most critical step in drug manufacturing due to its highly specialized nature, which makes it difficult to get products to market or clinical trials. In addition to being extremely costly, fill/finish operations are quite rightly subject to extreme scrutiny by regulatory agencies.

    We have recently seen more stringent requirements from the regulatory bodies, with aseptic fill/finish one of the main areas of focus and quality standards remaining a major challenge for some CMOs.

    Clients are rightly vigilant when placing their projects with sterile CMOs. By demonstrating robust and continuously improving quality systems and a strong regulatory track record with the MHRA, who are regarded globally as a gold standard, clients are reassured when dealing with our team, knowing our operations absolutely comply with prevailing regulations.

    Domestic market preference to have manufacturing located near to the demand could increase the presence of facilities in developing regions, but it will take time to build experience and confidence there. Aseptic fill finish is the highest risk mode of drug product manufacture, hence confidence in the facility is key.

    We expect to continue to experience growing demand from U.S. biotechs that are undertaking clinical trials in Europe. By choosing a GMP manufacturer based in Europe, drug developers can ensure compliance with the QP standards required to release a drug product for a European based clinical trial.

    In reality, the industry and our sector is truly global. Within drug development, clinical trials are now conducted all over the world. Most clients are concerned with many other factors beyond locality.

    CP: What do you think the future holds for the biologics fill/finish market?
    JA:
    The outsourcing sector will no doubt continue to grow over the next five years, with particular growth in the parenteral manufacturing space coming from biopharma companies as they begin to progress new drug products thanks to an increase in funding.

    Despite the demand for services, due to the substantial barriers to entry and increasing quality demands, we don’t expect to see many new players entering the market. While many CMOs continue to expand their offerings, there will continue to be demand for niche manufacturing services from specialist providers that can offer the flexibility needed to meet increasingly tight timescales in the drug development pipeline.

    Time and flexibility often have a very high influence on the selection of a fill/finish CMO partner, and clients can sometimes underestimate the complexity of setting up fill/finish operations that are suitable and scalable.

    As a result of this we are also seeing more experienced innovators engaging external support earlier in development, and some are seeking more strategic relationships that begin at an early stage of development but consider the needs of later stage supply.

    CP: How will Symbiosis capitalize on this? What does the future hold for the company?
    JA:
    As a result of increased global demand, Symbiosis has grown by around 40% over the last year and has also continued to recruit steadily, increasing staff by 30% to meet demand for its specialist aseptic fill/finish service.

    Europe and the U.S. continue to be our strongest markets. We have experienced significant growth in the U.S. in recent years and expect this to continue as demand for our expertise in filling biologic and small molecule products, combined with our ability to offer rapid access to sterile manufacturing slots, has been very well received by preclinical and Phase I-III biotech and pharma companies.

    Since strengthening our U.S.-focused personnel and developing our relationships with networks like MassBio and ISPE, we have significantly grown our U.S. client base, which is projected to account for around half of our revenues in 2017.

    In January, we opened a commercial site in Cambridge, Boston, MA, to support our clients on both the East and West Coast U.S., and provide a base for reaching new customers in this territory.

    Regulatory compliance, technical capability and operational flexibility are still core to Symbiosis’ offerings. It’s about the level of service you can deliver to your customers, how quickly you can offer them access to your services, along with an absolute ability to consistently demonstrate regulatory compliance of the highest standards. 
    Related Searches
    • Clinical Trials
    • sterile manufacturing
    • Filling
    • Clinical Trial
    Suggested For You
    Kintor, Visum Enter COVID-19 Manufacturing Partnership Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Catalent Adds Cryogenic Capabilities at Philadelphia Facility Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    Metrics Names Stephanie Emory Associate Director of Pharma Development Metrics Names Stephanie Emory Associate Director of Pharma Development
    BioVersys Gets EIB Funds to Address Antimicrobial Resistance BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Vetter Development Service Vetter Development Service
    AJILITY: Intelligent Drug Product Manufacturing AJILITY: Intelligent Drug Product Manufacturing
    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans Agilex Biolabs Acquires TetraQ for APAC Expansion Plans
    Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    Moleculin Selects IQVIA Biotech to Advance COVID Treatment Moleculin Selects IQVIA Biotech to Advance COVID Treatment
    Cryoport Acquires Critical Transport Solutions Australia Cryoport Acquires Critical Transport Solutions Australia
    CordenPharma Enters Alliance with Nanos of South Korea CordenPharma Enters Alliance with Nanos of South Korea
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    GSK Supports Manufacture of Novavax’ COVID-19 Vaccine GSK Supports Manufacture of Novavax’ COVID-19 Vaccine
    Advanced Analytics Advancing Development of Genetic Vaccines Advanced Analytics Advancing Development of Genetic Vaccines

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20


    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    Trending
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • Sartorius Expands In The UK
    Breaking News
    • Waters and Genovis Enter Biopharmaceutical Partnership
    • Frontage Acquires Ocean Ridge Biosciences
    • AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    • TraceLink Introduces Opus Platform
    • Evotec to Build Second Biologics Mfg. Facility in Toulouse
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Probiotic Strain Evidenced to Reduce Iron Deficiency/Anemia Risk
    Longvida Curcumin Extract Receives ANVISA Approval in Brazil
    Curcugen Curcumin Formulation Evidenced to Attenuate Post-Exercise Inflammation
    Coatings World

    Latest Breaking News From Coatings World

    Keim-additec Hires Tyler John as Technical Sales Manager
    Nouryon Appoints Julie Aslaksen to Board of Directors
    RadTech Announces New Board Members, Secretary, Honorary Lifetime Member
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    J&J’s Veritas Vision System Receives FDA Clearance and CE Mark
    Viz.ai’s AI-Powered Platform Can Improve Outcomes for Stroke Patients
    FDA Breakthrough Device Designation Granted for pdSTIM System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Waters and Genovis Enter Biopharmaceutical Partnership
    Frontage Acquires Ocean Ridge Biosciences
    AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Do Americans Feel About Diversity in Beauty Advertising?
    Estée Lauder Companies Reaffirms Sustainability Goals for Earth Month
    Coty’s Lancaster Earns C2C Certified Material Health Certificate
    Happi

    Latest Breaking News From Happi

    It's Official! L'Oréal Gets New CEO on May 1
    New Beauty Brand sk*p Wants to Break Addiction to Plastic
    Provital Presents Apibreeze for Skin Care
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Global Graphics unveils new SmartDFE
    Channeled Resources installs new slitter in Toronto facility
    Kao Collins launches new website for printing inks and services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversation Launches Wipes Dispenser
    Because Market Debuts Premium Plus Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Spinal Elements' Lucent 3D Additive Manufactured Interbodies Earn FDA Nod
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints imec, Soitec Executives to Europe Advisory Board
    TechBlick Announces Agenda For Next Printed, Hybrid, Structural, 3D Electronics Virtual Event
    NREL Takes Novel Approach to 3D-Printed Water Power Prototypes

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login